NCT06868732 2026-03-30Evaluation of JSKN016 Combination Therapy in Subjects With NSCLCJiangsu Alphamab Biopharmaceuticals Co., LtdPhase 1 Recruiting288 enrolled
NCT05364073 2026-03-13Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) MutationsArriVent BioPharma, Inc.Phase 1 Active not recruiting160 enrolled